FDA approves Ayvakit for unresectable, metastatic gastrointestinal stromal tumors harboring rare mutation

The FDA today approved avapritinib for the treatment of adults with unresectable or metastatic gastrointestinal stromal tumors that harbor a platelet-derived growth factor receptor alpha, or PDGFRA, exon 18 mutation.This approval — which includes gastrointestinal stromal tumors (GIST) with PDGFRA D842V mutation, the most common exon 18 mutation — marks the first of a targeted therapy to treat this rare mutation in these tumors. Up to about 10% of patients with GIST harbor a PDGFRA mutation.“GIST harboring a PDGFRA exon 18 mutation do not respond to standard therapies forRead More

Share on facebook
Share on twitter
Share on linkedin